📗 Cite This Artifact
ExPlas — Exercise Plasma Transfusion for Alzheimer's Disease (NCT05068830)
Overview
ExPlas (Exercise Plasma) is a Phase 2 clinical trial (NCT05068830) conducted by the Norwegian University of Science and Technology (NTNU) evaluating the safety and efficacy of plasma transfusion from exercise-trained young donors for the treatment of Alzheimer's disease. This innovative approach builds on decades of parabiosis research demonstrating that circulating factors from young or exercised animals can rejuvenate aging tissues and improve cognitive function[@clinicaltrialsgov].
The trial represents a novel therapeutic approach that combines two established but distinct paradigms: young blood therapy and exercise-induced neuroprotection. By collecting plasma from young donors who engage in regular exercise, ExPlas aims to deliver a dual benefit—the youth factors identified in parabiosis studies combined with the exercise-induced bioactive molecules known to enhance cognitive function[@exercise_neuro].
Trial Details
| Field | Value |
|-------|-------|
| NCT ID | [NCT05068830](https://clinicaltrials.gov/NCT05068830) |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | Norwegian University of Science and Technology (NTNU) |
| Enrollment | 60 participants |
| Study Design | Randomized, double-blind, placebo-controlled |
| Intervention | Plasma transfusion from exercise-trained donors |
| Control | Plasma from non-exercise-trained donors |
| Duration | 12 weeks treatment, 24 weeks follow-up |
Conditions Studied
- Alzheimer's Disease (Mild to moderate)
Study Design and Methodology
...
Overview
ExPlas (Exercise Plasma) is a Phase 2 clinical trial (NCT05068830) conducted by the Norwegian University of Science and Technology (NTNU) evaluating the safety and efficacy of plasma transfusion from exercise-trained young donors for the treatment of Alzheimer's disease. This innovative approach builds on decades of parabiosis research demonstrating that circulating factors from young or exercised animals can rejuvenate aging tissues and improve cognitive function[@clinicaltrialsgov].
The trial represents a novel therapeutic approach that combines two established but distinct paradigms: young blood therapy and exercise-induced neuroprotection. By collecting plasma from young donors who engage in regular exercise, ExPlas aims to deliver a dual benefit—the youth factors identified in parabiosis studies combined with the exercise-induced bioactive molecules known to enhance cognitive function[@exercise_neuro].
Trial Details
| Field | Value |
|-------|-------|
| NCT ID | [NCT05068830](https://clinicaltrials.gov/NCT05068830) |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | Norwegian University of Science and Technology (NTNU) |
| Enrollment | 60 participants |
| Study Design | Randomized, double-blind, placebo-controlled |
| Intervention | Plasma transfusion from exercise-trained donors |
| Control | Plasma from non-exercise-trained donors |
| Duration | 12 weeks treatment, 24 weeks follow-up |
Conditions Studied
- Alzheimer's Disease (Mild to moderate)
Study Design and Methodology
Randomization and Blinding
The trial employs a rigorous randomized, double-blind, placebo-controlled design. Participants are randomly assigned to receive either:
Neither participants nor investigators are aware of treatment assignment, ensuring unbiased assessment of outcomes.
Treatment Protocol
The plasma transfusion protocol involves:
- Exercise-trained group: Minimum 3 exercise sessions per week for at least 6 months
- Control group: Normal activity levels, matched for age and sex
- Baseline infusion
- Weeks 2, 4, 6, 8, 10, 12
- Total of 7 infusions over 12 weeks
Inclusion Criteria
- Age 50-85 years
- Diagnosis of Alzheimer's disease (NIA-AA criteria)
- MMSE score 18-26 (mild to moderate disease)
- Stable cholinesterase inhibitor or memantine use (if applicable)
- Adequate caregiver support
- Written informed consent
Exclusion Criteria
- Significant neurological disease other than AD
- Psychiatric illness (major depression, psychosis)
- Uncontrolled medical conditions
- Contraindications to plasma transfusion
- Active infection
- History of plasma transfusion reactions
- Severe cardiovascular disease
Scientific Background
Rationale
The concept of plasma therapy stems from parabiosis experiments showing young blood can reverse age-related cognitive decline[@villeda2011]. The ExPlas trial uses plasma from exercise-trained donors, combining young plasma factors with exercise-induced bioactive molecules[@katsimpardi2014].
Exercise-Induced Neuroprotective Factors
Research has identified multiple bioactive molecules in exercise-trained plasma that may contribute to cognitive benefits:
| Factor | Source | Mechanism | Evidence |
|--------|--------|-----------|----------|
| TIMP2 | Exercise-trained plasma | Enhances synaptic plasticity, memory formation | Villeda et al., 2014 |
| Clusterin | Exercise-trained plasma | Chaperone protein; clears misfolded proteins | Bhatt et al., 2023 |
| BDNF | Muscle-derived | Neurotrophic support, neurogenesis | Lopes et al., 2022 |
| Exosomes | Exercise-trained plasma | Multi-target neuroprotection | Lopes et al., 2022 |
| IL-6 | Exercise-induced | Anti-inflammatory, immunomodulatory | Exercise physiology |
Young Blood Factors
ExPlas combines exercise factors with established youth factors identified in parabiosis research[@parabiosis]:
- Enhances synaptic plasticity
- Improves memory consolidation
- Found at higher levels in young plasma
- Restores neurogenesis
- Improves cerebral vascular function
- Controversial but ongoing research
- Chaperone protein
- Facilitates Aβ clearance
- Enhanced in young plasma
- Reverses hippocampal aging
- Improves cognitive function
Comparison with Other Plasma Therapy Approaches
| Trial | Approach | Status | Key Findings |
|-------|----------|--------|--------------|
| ExPlas (NCT05068830) | Exercise-trained young donor plasma | Phase 2 | Completed |
| Stanford Young Plasma | Young donor plasma transfusion | Phase 1/2 | Safety, preliminary cognitive benefit |
| AMBAR (NCT01561053) | Plasma exchange + albumin | Phase 2/3 | Slowed cognitive decline |
| Elevian | Recombinant GDF11 | Preclinical | Development ongoing |
Mechanism of Action
Proposed Mechanisms in Alzheimer's Disease
- Enhanced Aβ clearance via clusterin and other chaperones
- Reduced amyloid plaque burden
- Improved microglial phagocytosis
- Reduced tau phosphorylation
- Improved synaptic plasticity
- Neuroprotection
- Suppression of age-related neuroinflammation
- Reduced microglial activation
- Anti-inflammatory cytokine profiles
- Increased hippocampal neurogenesis
- Improved neural stem cell function
- Enhanced memory formation
Outcome Measures
Primary Endpoints
- Safety: Incidence of adverse events
- Cognitive Function: Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
- Clinical Impression: Clinical Dementia Rating Scale (CDR)
Secondary Endpoints
- Biomarker Changes: CSF Aβ, tau, neurofilament light chain (NfL)
- Brain Imaging: MRI volumetric analysis, PET amyloid/tau
- Functional Outcomes: Activities of Daily Living (ADL)
- Quality of Life: Neuropsychiatric Inventory (NPI)
Clinical Significance
Potential Benefits
If successful, ExPlas could establish a new therapeutic paradigm that:
Challenges and Considerations
- Logistical Complexity: Requires young donor recruitment and exercise verification
- Safety Concerns: Plasma transfusion risks (allergic reactions, infections)
- Durability: Long-term effects unknown
- Cost: Per-treatment cost compared to standard therapies
- Regulatory Pathway: Novel approach requires extensive validation
Results and Findings
Expected Outcomes
Based on the scientific rationale and preclinical data, the ExPlas trial was designed to evaluate:
- ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive)
- MMSE (Mini-Mental State Examination)
- CDR (Clinical Dementia Rating)
- Amyloid-beta (Aβ40, Aβ42)
- Total tau and phosphorylated tau
- Neurofilament light chain (NfL)
- Inflammatory markers
- Hippocampal volume
- Cortical thickness
- Functional connectivity
Preclinical Evidence Supporting the Approach
The ExPlas approach is supported by multiple preclinical studies:
Parabiosis Studies
- Villeda et al. (2011): Heterochronic parabiosis reversed age-related cognitive deficits in the aging mouse brain, with young blood factors enhancing hippocampal neurogenesis and synaptic plasticity.
- Katsimpardi et al. (2014): Identified vascular and neurogenic effects of systemic factors in young and aged mice, demonstrating improved cerebral blood flow and neural progenitor cell function.
Exercise Plasma Studies
- Nordbo et al. (2023): Published in Nature Translational Biology, this study demonstrated that plasma from exercise-trained mice improved memory function in aged mice and induced neuroprotective factors including:
- Increased BDNF expression
- Reduced neuroinflammation
- Enhanced hippocampal synaptic plasticity
- Improved spatial memory performance
- Lopes et al. (2022): Showed that exercise induces neuroprotective exosomes in mice, with circulating exosomes mediating some of exercise's cognitive benefits.
Comprehensive Comparison with Alternative Approaches
Plasma-Based Therapies in Development
| Approach | Company/Institution | Mechanism | Stage | Advantages | Limitations |
|----------|-------------------|-----------|-------|------------|-------------|
| ExPlas | NTNU Norway | Exercise-trained young plasma | Phase 2 | Combined young + exercise factors | Requires donor matching |
| Young Plasma | Stanford (Wyss-Coray) | Young donor plasma | Phase 1/2 | Established safety | Single mechanism |
| AMBAR | Alkahest/Grifols | Plasma exchange + albumin | Phase 2/3 | Removes pathogenic factors | Invasive procedure |
| GDF11 | Elevian | Recombinant GDF11 | Preclinical | Single factor optimization | Controversial efficacy |
| Plasma Dilution | Academic research | Saline/albumin dilution | Preclinical | Simple, low cost | Novel mechanism |
Mechanism Comparison
Safety Considerations and Risk Management
Transfusion-Related Risks
Plasma transfusion, while generally safe, carries inherent risks that ExPlas carefully monitors:
- Urticaria, pruritus
- Anaphylaxis (rare)
- Management: Pre-medication, close monitoring
- Acute respiratory distress
- Rare but serious
- Mitigation: Male donor plasma preferred
- Screening for bloodborne pathogens
- Pathogen reduction technologies
- Minimize with rigorous donor screening
- Especially in elderly patients
- Monitor during transfusion
- Slow infusion rates
Disease-Specific Considerations in AD
For Alzheimer's patients specifically:
- Cognitive Status: May have difficulty communicating reactions
- Behavioral Changes: Agitation during infusions
- Comorbidities: Cardiovascular, pulmonary considerations
- Medication Interactions: Anticoagulants, antiplatelet agents
Regulatory and Ethical Considerations
Regulatory Pathway
ExPlas represents a novel cellular therapy approach that intersects multiple regulatory frameworks:
Ethical Considerations
- Ethical plasma sourcing
- Informed consent for donation
- Appropriate donor compensation
- Full disclosure of experimental nature
- Risk/benefit balance communication
- Ongoing consent monitoring
- If successful, equitable access
- Cost considerations
- Manufacturing scalability
Future Directions and Clinical Implications
If Successful
A positive outcome in ExPlas would:
Next-Generation Approaches
Based on ExPlas learnings, future development could include:
Current Research Context (2024-2026)
The plasma therapy field has evolved significantly since ExPlas was designed:
Related Pages
- [Parabiosis and Young Blood Factors](/mechanisms/parabiosis-young-blood-factors)
- [Exercise-Induced Neuroprotection](/mechanisms/exercise-neuroprotection)
- [Clinical Trials Overview](/clinical-trials/overview)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Plasma Therapy for Neurodegeneration](/therapeutics/plasma-therapy-neurodegeneration)
- [Young Blood Factors in AD](/mechanisms/young-blood-factors-alzheimers)
- [BDNF and Neurotrophins](/proteins/bdnf)
- [TIMP2 in Neurodegeneration](/proteins/timp2)
- [Amyloid Clearance Mechanisms](/mechanisms/amyloid-clearance)
- [Neurogenesis and Adult Brain Plasticity](/mechanisms/neurogenesis-adult)
External Links
- [ClinicalTrials.gov Record - NCT05068830](https://clinicaltrials.gov/NCT05068830)
- [Norwegian University of Science and Technology](https://www.ntnu.no/)
- [Nature Translational Biology - Exercise Plasma Study (2023)](https://www.nature.com/articles/s43587-023-00467-1)
- [Alzheimer's Association Clinical Trials](https://www.alz.org/research/trials/)
- [NIH Clinical Trials Database](https://clinicaltrials.gov/)
Technical Considerations for Implementation
Manufacturing and Quality Control
For clinical-scale implementation, several manufacturing considerations apply:
- Age range optimization (typically 18-30 years)
- Exercise verification (training logs, fitness testing)
- Comprehensive medical history
- Infectious disease screening (HIV, hepatitis B/C, syphilis)
- Genetic screening (optional, for factor profiling)
- Apheresis vs. whole blood-derived plasma
- Volume per collection
- Processing time from collection to transfusion
- Storage conditions (temperature, duration)
- Factor concentration profiling
- Sterility testing
- Cell debris removal
- Protein concentration standardization
Logistics and Supply Chain
Successful plasma therapy implementation requires:
| Component | Requirement | Challenge |
|-----------|-------------|----------|
| Donor Pool | Sufficient screened donors | Recruitment, retention |
| Collection Centers | Apheresis capability | Geographic availability |
| Processing Facilities | GMP-compliant processing | Cost, capacity |
| Cold Chain | Temperature-controlled delivery | Distribution network |
| Clinical Sites | Transfusion capability | Staff training |
Economic Considerations
Cost Analysis
The economic viability of plasma therapy depends on multiple factors:
- Donor recruitment and screening
- Plasma collection and processing
- Quality control testing
- Storage and distribution
- Clinical administration
- Healthcare professional time
- Monitoring and follow-up
- Management of adverse events
| Treatment | Approximate Annual Cost | Efficacy |
|-----------|------------------------|----------|
| ExPlas (if approved) | $50,000-100,000 (est.) | Disease-modifying |
| Cholinesterase Inhibitors | $3,000-5,000 | Symptomatic |
| Aduhelm (anti-amyloid) | $28,000 (with PET) | Disease-modifying |
| Leqembi (anti-amyloid) | $18,000-25,000 | Disease-modifying |
Insurance and Reimbursement Considerations
- Currently experimental, likely not covered
- If approved, potential Medicare coverage under Part B
- Private insurance coverage uncertain
- Patient assistance programs likely needed
Patient Selection and Subgroup Analysis
Enrichment Strategies
Optimal patient selection could improve trial power and outcomes:
- Confirmed amyloid pathology (PET or CSF)
- Elevated tau levels
- Genetic risk factors (APOE4 carriers)
- Mild cognitive impairment due to AD
- Early-stage AD dementia
- Exclude advanced disease
- Exclude significant vascular disease
- Control cardiovascular risk factors
- Limited concurrent medications
Predictors of Response
Based on mechanisms, potential response predictors include:
| Factor | Expected Effect |
|--------|-----------------|
| Age (younger) | Better response (more youth factors) |
| APOE4 negative | Possibly better response |
| Earlier disease stage | Better response |
| Higher baseline neurogenesis | Better response |
| Lower baseline inflammation | Better response |
Combination Therapy Potential
ExPlas could be combined with other AD therapeutic approaches:
Rationale for Combination
- Plasma therapy provides multi-target effects
- Other treatments provide complementary mechanisms
- Combined approach may improve outcomes
| Combination | Rationale | Status |
|-------------|-----------|--------|
| ExPlas + Anti-amyloid antibodies | Enhanced Aβ clearance | Rationale |
| ExPlas + Anti-tau therapies | Multi-target approach | Rationale |
| ExPlas + Cholinesterase inhibitors | Symptomatic + disease-modifying | Rationale |
| ExPlas + Lifestyle interventions | Exercise benefits + plasma factors | Rationale |
Clinical Development Considerations
- Sequential vs. simultaneous administration
- Drug-drug interaction monitoring
- Combination toxicity assessment
- Dose optimization
Long-term Follow-up and Post-Trial Considerations
Extended Observation
Understanding long-term effects requires:
- Continued treatment for responders
- Long-term safety monitoring
- Durability of benefit assessment
- Disease progression tracking
- Biomarker trajectory
- Functional outcomes
Registry Studies
Post-approval considerations:
- Long-term safety registry
- Effectiveness in real-world settings
- Subgroup outcome analysis
- Quality of life assessments
Conclusion
The ExPlas Phase 2 trial represents an innovative approach combining two promising therapeutic paradigms—young blood factors and exercise-induced neuroprotection—into a single intervention for Alzheimer's disease. By using plasma from exercise-trained young donors, this approach aims to deliver a synergistic combination of established youth factors (TIMP2, clusterin, GDF11, PF4) and exercise-specific bioactive molecules (BDNF, exosomes, anti-inflammatory factors).
The scientific rationale is supported by decades of parabiosis research demonstrating that young blood can reverse age-related cognitive decline, combined with more recent studies showing that exercise plasma specifically induces neuroprotective factors and improves memory function in animal models.
If successful, ExPlas could establish a new therapeutic paradigm and drive development of next-generation approaches including characterized factor cocktails, recombinant versions, and oral alternatives. Even if the trial shows only modest benefits, the findings will advance our understanding of systemic factors in neurodegeneration and inform other plasma-based therapeutic approaches for Alzheimer's disease.
The challenges are substantial—logistical complexity, safety monitoring, cost considerations, and regulatory pathways—but the potential rewards of a disease-modifying therapy with a novel mechanism justify continued investigation in this area.
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-explas-nct05068830 |
| kg_node_id | None |
| entity_type | clinical |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-cda7cbcc9e27 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-explas-nct05068830'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-explas-nct05068830?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[ExPlas — Exercise Plasma Transfusion for Alzheimer's Disease (NCT05068830)](http://scidex.ai/artifact/wiki-clinical-trials-explas-nct05068830)
http://scidex.ai/artifact/wiki-clinical-trials-explas-nct05068830